Astrazeneca stock: buy or sell?
February 21st, 2020
AstraZeneca PLC develops, manufactures, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, infection, gastrointestinal, and neuroscience diseases worldwide.
Should I buy Astrazeneca stock?You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. That's why is so important to choose your own trading plan that matches with your character as inversor. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
Currently, Astrazeneca stock doesn't match any of these trading strategies, so our recommendation is not to buy.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Astrazeneca stock a buy?
Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness.Unfortunately, we couldn't find any rating for AZN stock for the last month.
Astrazeneca stock analysis
Astrazeneca crossed up the simple moving average line of 50 days today and closed at $50.17, jumped a 2.51%.
Astrazeneca shares broke up the simple moving average line of 50 days today and closed at $50.17, jumped a 2.51%. On Jan 17th, AZN hit a new all time high, pushing higher than on December tops. Check different trading setups that use ATHs as triggers.
Astrazeneca ended this week at $50.17 and rocketed a brilliant 4.85%.
AZN marked an uptrend of rising tops and rising bottoms. Since its last top by mid January at $51.55, price slid and bounced up back from $47.40. Breaking down under $47.40 would cancel the current uptrend and it might test lower supports. Note that $51.55 might act as a resistance line. Not so far away is the last price record Astrazeneca marked by mid January. Early June AZN price bounced up over the SMA of 40 weeks that acted as support stopping new slides. Since late July 2019 when SMA10w and SMA20w crossed up, AZN price gained $10.46 per share (26.34%).
Astrazeneca stock price history
Astrazeneca IPO was on May 12th, 1993 at $0.44 per share1. Since then, AZN stock surged a 11,302.30%, with an average of 434.70% per year. If you had invested $1,000 in Astrazeneca stock in 1993, it would worth $113,023.00 today.
1: Adjusted price after possible price splits or reverse-splits.
Astrazeneca stock historical price chart
AZN stock reached all-time highs on January/17 with a price of $51.55.
Astrazeneca stock price targetPredicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. For the last month we have not found any price forecast for Astrazeneca stock by any trusted analyst.
Financials and fundamental analysis
Earnings date and Earnings per ShareAstrazeneca presented extraordinary results for 2018-Q4 . Astrazeneca boosted Earnings per Share (EPS) by 116.40%, beating experts of $0.73. Astrazeneca posted $1.58.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2018, Astrazeneca annual turnover slightly fell a lame -1.67% to $22,090.00 M USD from $22,465.00 marked in 2017. Likewise, its income margin (compared to revenues) declined to 9.76%, that is $2,155.00 million.
|2013||$16,450 M||-||$1,640 M10.0%||-|
|2014||$26,095 M||58.63%||$1,233 M4.7%||-24.82%|
|2015||$24,708 M||-5.32%||$2,825 M11.4%||129.12%|
|2016||$23,002 M||-6.90%||$3,499 M15.2%||23.86%|
|2017||$22,465 M||-2.33%||$3,001 M13.4%||-14.23%|
|2018||$22,090 M||-1.67%||$2,155 M9.8%||-28.19%|
Quarterly financial resultsAstrazeneca reported $6,417.00 million in sales for 2018-Q4, a 20.17% improvement compared to previous quarter. Reported quarter income marked $1,034.00 M with a profit margin of 16.11%. Profit margin escalated a 8.04% compared to previous quarter when profit margin was 8.07%. When comparing sales to same quarter last year, Astrazeneca sales marked a brilliant increase and climbed a 11.08%. Looking back to recent quarterly results, Astrazeneca posted 2 negative quarters in a row.
|2017-Q2||$3,950 M||-||$373 M9.4%||-|
|2017-Q3||$6,232 M||57.77%||$686 M11.0%||84.13%|
|2017-Q4||$5,777 M||-7.30%||$1,301 M22.5%||89.65%|
|2018-Q1||$5,178 M||-10.37%||$340 M6.6%||-73.87%|
|2018-Q2||$5,155 M||-0.44%||$350 M6.8%||2.94%|
|2018-Q3||$5,340 M||3.59%||$431 M8.1%||23.14%|
|2018-Q4||$6,417 M||20.17%||$1,034 M16.1%||139.91%|
|2019-Q1||$5,491 M||-14.43%||$593 M10.8%||-42.65%|
Astrazeneca ownershipWhen you are planning to buy shares of a stock, it's worth to review its ownership structure.
Astrazeneca shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 0.00% of all shares.
In case of Astrazeneca stock, 18.39% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for AZN stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to Astrazeneca:
|Market cap||$131.4 B|
|Total shares||2,620.0 M|
|Float shares||2,620.0 M|
|- Institutional holdings (%)||18.4%|
|- Insider holdings (%)||0.0%|
|Shares in short selling||0.0%|
|Friday, February 21st, 2020|
|Day range||$49.68 - $50.25|
|Average true range||$0.83|
|50d mov avg||$49.60|
|100d mov avg||$47.97|
|200d mov avg||$44.74|
Astrazeneca performancePerformance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. We chose as the bechmarking frame for Astrazeneca stock.
Astrazeneca competitorsUnfortunately, we could not find any public company that could be defined as Astrazeneca competitor. This doesn't mean Astrazeneca does not have any competitor in the market, it's just we could not detected it.
Latest Astrazeneca stock news
- Seeking AlphaAstraZeneca Calquence CLL Data Sets It Up For Regulatory Submissions In 2019June 26, 2019
- Seeking AlphaAn FDA Win For AstraZeneca Shifts To An Expanded Label In The Type 2 Diabetes MarketMay 21, 2019
- Seeking AlphaGlaxoSmithKline & AstraZeneca, Two Brexit Cancellation Income PlaysApril 29, 2019
- InvestorPlaceIs AstraZeneca Stock Worth Buying Before Earnings?April 10, 2019
- InvestorPlaceAstraZeneca News: Why AZN Stock Is Sliding Lower TodayMarch 29, 2019